The DOI matches its Crossref record.
Targeting CD24 for Treatment of Colorectal and Pancreatic Cancer by Monoclonal Antibodies or Small Interfering RNA
Open accessAbstract
CD24 is a potential oncogene reported to be overexpressed in a large variety of human malignancies. We have shown that CD24 is overexpressed in 90% of colorectal tumors at a fairly early stage in the multistep process of carcinogenesis. Anti-CD24 monoclonal antibodies (mAb) induce a significant growth inhibition in colorectal and pancreatic cancer cell lines that express the protein. This study is designed to investigate further the effects of CD24 down-regulation using mAb or small interfering RNA in vitro and in vivo. Western blot analysis showed that anti-CD24 mAb induced CD24 protein down-regulation through lysosomal degradation. mAb augmented growth inhibition in combination with five classic chemotherapies. Xenograft models in vivo showed that tumor growth was significantly reduced in mAb-treated mice. Similarly, stable growth inhibition of cancer cell lines was achieved by down-regulation of CD24 expression using short hairpin RNA (shRNA). The produced clones proliferated more slowly, reached lower saturation densities, and showed impaired motility. Most importantly, down-regulation of CD24 retarded tumorigenicity of human cancer cell lines in nude mice. Microarray analysis revealed a similar pattern of gene expression alterations when cells were subjected to anti-CD24 mAb or shRNA. Genes in the Ras pathway, mitogen-activated protein kinase, or BCL-2 family and others of oncogenic association were frequently down-regulated. As a putative new oncogene that is overexpressed in gastrointestinal malignancies early in the carcinogenesis process, CD24 is a potential target for early intervention in the prevention and treatment of cancer. [Cancer Res 2008;68(8):2803–12]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors
Rimkus, T., Carpenter, R., Qasem, S., Chan, M., & Lo, H.-W. (2016) · Cancers · doi:10.3390/cancers8020022 · Cited by 581
Lee, C. J., Dosch, J., & Simeone, D. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6702 · Cited by 374
Belfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.040 · Cited by 294
Extraction and analysis of signatures from the Gene Expression Omnibus by the crowd
Wang, Z., Monteiro, C. D., Jagodnik, K. M., Fernandez, N. F., Gundersen, G. W., Rouillard, A. D., Jenkins, S. L., Feldmann, A. S., Hu, K. S., McDermott, M. G., et al. (2016) · Nature Communications · doi:10.1038/ncomms12846 · Cited by 256
CD24 Is an Effector of HIF-1–Driven Primary Tumor Growth and Metastasis
Thomas, S., Harding, M. A., Smith, S. C., Overdevest, J. B., Nitz, M. D., Frierson, H. F., Tomlins, S. A., Kristiansen, G., & Theodorescu, D. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3666 · Cited by 128
Metadata
- Authors
- Sagiv, E., Starr, A., Rozovski, U., Khosravi, R., Altevogt, P., Wang, T., & Arber, N.
- Venue
- Cancer Research
- Published
- 2008-04-15
- Volume
- 68
- Issue
- 8
- Pages
- 2803-2812
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2154207271
- Cited by
- 163
- References
- 0
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting CD24 for Treatment of Colorectal and Pancreatic Cancer by Monoclonal Antibodies or Small Interfering RNA. https://app.cochat.ai/papers/10.1158/0008-5472.can-07-6463
- The paper
- Sagiv, E., Starr, A., Rozovski, U., Khosravi, R., Altevogt, P., Wang, T., & Arber, N. (2008). Targeting CD24 for Treatment of Colorectal and Pancreatic Cancer by Monoclonal Antibodies or Small Interfering RNA. Cancer Research. https://doi.org/10.1158/0008-5472.can-07-6463
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.